News for Sanofi (SNY)

Press release: Availability of the Q2 2025 Aide mémoire

Riliprubart granted orphan drug designation in Japan for chronic inflammatory demyelinating polyneuropathy

PR NewswireCAMBRIDGE, Mass., June 26, 2025 New fund supports nonprofit partners working to address social drivers of health and strengthen community well-b

**media[661466]**

PR NewswireNEW YORK, June 22, 2025 NEW YORK, June 22, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi"

**media[659912]**

**media[659911]**

PR NewswireNEW YORK, June 17, 2025 NEW YORK, June 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi"

[url="]The Schall Law Firm[/url], a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Sanofi (”

Sanofi (NASDAQ:SNY) is one of the 11 Best Drug Stocks to Buy According to Hedge Funds. Berenberg Bank analyst Luisa Hector maintained a Buy rating on Sanofi (NASDAQ:SNY) on June 12, setting a price target of €118.00. The rating followed the company’s presentation at the Goldman Sachs 46th Annual Global Healthcare Conference on June 10, highlighting […]

Sanofi (NASDAQ:SNY) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 4:00 PM ETCompany ParticipantsBrian Foard - Executive VP &...

Sanofi (SNY) boosts Beyfortus production to meet growing RSV vaccine demand ahead of 2025–2026 season.

**media[648941]**

PR NewswireNEW YORK, June 7, 2025 NEW YORK, June 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" o

Sanofi Launches 2025 Global Employee Stock Purchase Plan

**media[643889]**

Sanofi SA (NASDAQ:SNY) on Monday agreed to acquire Blueprint Medicines Corporation (NASDAQ:BPMC). The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the U.S. and the EU, and a promising advanced and early-stage immunology pipeline. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), a rare immunology disease, which is characterized by the accumulation and activation of aberrant mast cells

PR NewswirePARIS and CAMBRIDGE, Mass., June 2, 2025 Adds fast-growing and only approved medicine for advanced and indolent systemic mastocytosis to the San

Sanofi faces setbacks after itepekimab’s Phase 3 COPD failure, removing a key growth prospect and highlighting reliance on Dupixent. Read more about why SNY is still a Buy.